Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gregory Delange

Plastic Surgery Palm Beach Gardens, FL Medical Doctor

NPI 1497816169 CMS profile 662008

2865 Pga Blvd, Palm Beach Gardens, FL 33410

Open in the dashboard

General payments

$22,998

445 records reported · program years 2019–2025

Research payments

$1,250

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gregory Delange of Palm Beach Gardens, FL is reported in the CMS Open Payments database as having received $22,998 across 445 general payments and $1,250 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,218 35
2024 General $2,072 57
2023 General $3,226 60
2022 General $2,226 62
2022 Research $1,000 1
2021 General $2,745 67
2020 General $1,057 48
2020 Research $250 1
2019 General $10,454 116

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gregory Delange
  • Plastic Surgery median
  • Middle half of Plastic Surgery
  • National median

In program year 2025, general payments to Gregory Delange were reported at $1,218. Among 3,701 Plastic Surgery profiles paid that year, the median was $379 and the middle half received between $138 and $1,100.

Show as a table
Year Gregory Delange Plastic Surgery median Middle half National median
2019 $10,454 $371 $122–$1,483 $163
2020 $1,057 $158 $52–$438 $114
2021 $2,745 $249 $87–$752 $132
2022 $2,226 $274 $102–$793 $149
2023 $3,226 $299 $113–$891 $160
2024 $2,072 $361 $124–$1,062 $164
2025 $1,218 $379 $138–$1,100 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $7,829 131 payments
  2. Merz North America, Inc. $5,722 93 payments
  3. Sientra, Inc. $3,723 41 payments
  4. Revance Therapeutics, Inc. $1,401 14 payments
  5. AbbVie, Inc. $1,364 53 payments
  6. Galderma Laboratories, L.P. $1,001 72 payments
  7. Dilon Technologies, Inc. $503 13 payments
  8. Integra LifeSciences Corporation $396 4 payments
  9. TELA Bio, Inc. $388 6 payments
  10. Musculoskeletal Transplant Foundation Inc. $310 6 payments
  11. Other $361 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $16,724 437 payments
  2. Gift $5,108 3 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $750 3 payments
  4. Travel and Lodging $416 2 payments
Products named General payments · program years 2019–2025
  1. NATRELLE $6,702 69 payments
  2. SIENTRA HIGH STRENGTH COHESIVE SILICONE GEL BREAST IMPLANT $3,723 41 payments
  3. Xeomin $3,628 58 payments
  4. ASCLERA $2,629 39 payments
  5. DAXXIFY $1,261 13 payments
  6. HEMOBLAST BELLOWS $503 13 payments
  7. BOTOX $487 31 payments
  8. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastic Surgery $451 12 payments
  9. BOTOX COSMETIC $418 20 payments
  10. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastics $408 25 payments
  11. Other $2,085 60 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Sientra, Inc. $1,250 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

366

Median for Plastic Surgery: 39

Drug cost

$1,762

Median for Plastic Surgery: $219

Branded share of claims

48.6%

Median for Plastic Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cephalexin Generic 123 $638
Valacyclovir Valacyclovir Hcl Brand 27 $394
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 85 $360
Methylprednisolone Generic 33 $183
Ondansetron Odt Ondansetron Brand 66 $144
Diazepam Generic 32 $43

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 700 Part D prescribers listed as Plastic Surgery; they describe a distribution and say nothing about conduct.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DAXXIFY
  • REVANCE THERAPEUTICS, INC. $858
$858 — —
DYSPORT
  • Galderma Laboratories, L.P. $206
$206 — —
BOTOX
  • AbbVie, Inc. $119
$119 — —
Xeomin
  • MERZ NORTH AMERICA, INC. $108
$108 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

447 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record